Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Minnesota
With
National Heart, Lung, and Blood Institute (NHLBI)
Aim 1 will examine how well HTN is controlled in the two groups at 6 months and 12 months after randomization. Aim 2 will examine mGlide usability for providers and provider experience and satisfaction with mGlide. It will also examine whether medications are managed differently for participants in the two groups. Aim 3 will examine whether patients are more satisfied with care in the mGlide group, whether they are more "activated" and have a greater sense of self-efficacy in managing their HTN.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stroke survivors (ischemic stroke or intra-parenchymal hemorrhage) or patients who have not had a stroke but carry a high risk of stroke or cardiovascular disease (CVD) events (\>7.5% over 10 years) as defined by the AHA/ACC guideline on risk stratification9
Diagnosis of uncontrolled HTN at the time of study enrollment (need not have stroke)
Uncontrolled blood pressure (BP) defined as SBP \> 150 mm Hg at the last 2 clinic visits in the 6 months prior to the screening date. Alternatively, if a patient was discharged from the hospital in the 6 months prior to screening and does not have 2 clinic visits after hospital discharge, at least one hospital SBP in the last 2 days of the hospital stay must be \>150 mm Hg. Screening of uncontrolled HTN will be based on Electronic Medical Record (EMR) BP data.
Capable and willing to comply with the entire study protocol
Able to give voluntary written informed consent
English, Spanish or Hmong speaking
Have a smart phone or mobile technology device (e.g. ipad) that can transmit BP from the BP monitor. iOS and Android Compatible. (iOS 7 or higher: iPhone 4 or higher, iPod touch 5th generation or higher, iPad 2nd generation or higher. Android 4.0 or higher.)
You may not be if
Unable or unwilling to give consent
Any severe co-morbid illness including end stage kidney disease (ESRD), end stage liver disease (ESLD) or when life expectancy is less than 1 year or if primary care provider feels that medical complexity of the patient precludes clinical trial participation
Unable to complete study tasks
Any serious psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance including significant delusional disorders such as schizophrenia and bipolar illness.
